600812 华北制药
交易中 08-28 14:46:10
资讯
新帖
简况
华北制药最新公告：子公司注射用赖氨匹林通过一致性评价并新增规格
证券之星 · 08-27 17:49
华北制药最新公告：子公司注射用赖氨匹林通过一致性评价并新增规格
每周股票复盘：华北制药（600812）Q2净利降57.01%
证券之星 · 08-23
每周股票复盘：华北制药（600812）Q2净利降57.01%
图解华北制药中报：第二季度单季净利润同比下降57.01%
证券之星 · 08-22
图解华北制药中报：第二季度单季净利润同比下降57.01%
华北制药最新公告：子公司获六价重组诺如病毒疫苗临床试验批准
证券之星 · 08-21
华北制药最新公告：子公司获六价重组诺如病毒疫苗临床试验批准
华北制药（600812）披露高级管理人员辞职公告，8月5日股价下跌2.26%
证券之星 · 08-05
华北制药（600812）披露高级管理人员辞职公告，8月5日股价下跌2.26%
华北制药：副总经理常志山因工作原因辞职
财中社 · 08-05
华北制药：副总经理常志山因工作原因辞职
股市必读：华北制药新发布《关于公司及下属子公司药品参与全国药品集中采购拟中选的公告》
证券之星 · 08-04
股市必读：华北制药新发布《关于公司及下属子公司药品参与全国药品集中采购拟中选的公告》
华北制药(600812.SH)：环孢素软胶囊等药品拟中选全国药品集中采购
智通财经 · 08-03
华北制药(600812.SH)：环孢素软胶囊等药品拟中选全国药品集中采购
冀中能源集团华北制药两项成果获评全国质量创新专业Ⅱ级奖项
市场资讯 · 07-31
冀中能源集团华北制药两项成果获评全国质量创新专业Ⅱ级奖项
每周股票复盘：华北制药（600812）获甲苯磺酸艾多沙班片注册证书
证券之星 · 06-28
每周股票复盘：华北制药（600812）获甲苯磺酸艾多沙班片注册证书
华北制药（600812）披露获得甲苯磺酸艾多沙班片《药品注册证书》，6月24日股价上涨0.9%
证券之星 · 06-24
华北制药（600812）披露获得甲苯磺酸艾多沙班片《药品注册证书》，6月24日股价上涨0.9%
华北制药(600812.SH)：甲苯磺酸艾多沙班片获药品注册证书
智通财经 · 06-23
华北制药(600812.SH)：甲苯磺酸艾多沙班片获药品注册证书
华北制药：公司对高级管理人员实施岗位目标责任制和绩效评价为中心的考核制度
证券之星 · 06-18
华北制药：公司对高级管理人员实施岗位目标责任制和绩效评价为中心的考核制度
华北制药：目前没有回购计划
证券之星 · 06-18
华北制药：目前没有回购计划
华北制药：2026年将继续围绕“五大板块”协同发展
证券之星 · 06-18
华北制药：2026年将继续围绕“五大板块”协同发展
华北制药：公司生产经营活动正常
证券之星 · 06-18
华北制药：公司生产经营活动正常
华北制药（600812）披露获得罗沙司他胶囊《药品注册证书》，5月25日股价下跌1.07%
证券之星 · 05-25
华北制药（600812）披露获得罗沙司他胶囊《药品注册证书》，5月25日股价下跌1.07%
每周股票复盘：华北制药（600812）获罗沙司他胶囊注册证
证券之星 · 05-24
每周股票复盘：华北制药（600812）获罗沙司他胶囊注册证
华北制药最新公告：获得罗沙司他胶囊药品注册证书
证券之星 · 05-22
华北制药最新公告：获得罗沙司他胶囊药品注册证书
华北制药（600812）披露2025年年度股东会决议公告，5月21日股价下跌1.04%
证券之星 · 05-21
华北制药（600812）披露2025年年度股东会决议公告，5月21日股价下跌1.04%
加载更多
公司概况
公司名称：
华北制药股份有限公司
所属行业：
医药制造业
上市日期：
1994-01-14
主营业务：
华北制药股份有限公司的主营业务是医药产品的研发、生产和销售。公司的主要产品是化学药、生物药、维生素及健康消费品、农兽药。
发行价格：
4.00
{"stockData":{"symbol":"600812","market":"SH","secType":"STK","nameCN":"华北制药","latestPrice":4.93,"timestamp":1787899570000,"preClose":4.95,"halted":0,"volume":12499493,"delay":0,"changeRate":-0.004,"floatShares":1716000000,"shares":1716000000,"eps":0.072,"marketStatus":"交易中","change":-0.02,"latestTime":"08-28 14:46:10","open":4.91,"high":4.95,"low":4.88,"amount":61367300,"amplitude":0.0141,"askPrice":4.93,"askSize":1163,"bidPrice":4.92,"bidSize":1110,"shortable":0,"etf":0,"ttmEps":0.072,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1787900400000},"marketStatusCode":2,"adr":0,"adjPreClose":4.95,"symbolType":"stock","openAndCloseTimeList":[[1787880600000,1787887800000],[1787893200000,1787900400000]],"highLimit":5.45,"lowLimit":4.46,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1715730370,"isCdr":false,"pbRate":1.54,"roa":"--","peRate":68.472222,"roe":"1.15%","epsLYR":0.107,"committee":0.002715,"marketValue":8459000000,"turnoverRate":0.0073,"status":1,"floatMarketCap":8459000000},"requestUrl":"/m/hq/s/600812","defaultTab":"news","newsList":[{"id":"2662707587","title":"华北制药最新公告：子公司注射用赖氨匹林通过一致性评价并新增规格","url":"https://stock-news.laohu8.com/highlight/detail?id=2662707587","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662707587?lang=zh_cn&edition=full","pubTime":"2026-08-27 17:49","pubTimestamp":1787824175,"startTime":"0","endTime":"0","summary":"华北制药(600812.SH)公告称，公司全资子公司深圳华药南方制药有限公司收到国家药监局核准签发的注射用赖氨匹林(0.9g、1.8g)《药品补充申请批准通知书》，该产品通过仿制药质量和疗效一致性评价，并新增1.8g规格。该药品用于不适用于口服给药的发热及轻、中度疼痛治疗。2025年该产品销售收入1173万元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700041841.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600812","BK0191","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661111282","title":"每周股票复盘：华北制药（600812）Q2净利降57.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661111282","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661111282?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:04","pubTimestamp":1787421855,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，华北制药报收于4.91元，较上周的5.04元下跌2.58%。本周，华北制药8月18日盘中最高价报5.22元。股本股东变化股东户数变动截至2026年6月30日，华北制药股东户数为8.86万户，较3月31日减少3223户，减幅3.51%。业绩披露要点财务报告华北制药2026年中报显示，上半年主营收入42.2亿元，同比下降20.01%；归母净利润6384.59万元，同比下降48.3%；扣非净利润5857.59万元，同比下降51.16%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600812","BK0028","BK0239","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661041294","title":"图解华北制药中报：第二季度单季净利润同比下降57.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661041294","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661041294?lang=zh_cn&edition=full","pubTime":"2026-08-22 01:55","pubTimestamp":1787334938,"startTime":"0","endTime":"0","summary":"证券之星消息，华北制药2026年中报显示，上半年度公司主营收入42.2亿元，同比下降20.01%；归母净利润6384.59万元，同比下降48.3%；扣非净利润5857.59万元，同比下降51.16%；其中2026年第二季度，公司单季度主营收入20.66亿元，同比下降23.49%；单季度归母净利润2837.31万元，同比下降57.01%；单季度扣非净利润2631.17万元，同比下降59.35%；负债率67.49%，投资收益3163.22万元，财务费用1.64亿元，毛利率27.04%。财报数据概要请见下图:本文数据来源于华北制药2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200002066.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600812"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661260210","title":"华北制药最新公告：子公司获六价重组诺如病毒疫苗临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2661260210","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661260210?lang=zh_cn&edition=full","pubTime":"2026-08-21 20:00","pubTimestamp":1787313643,"startTime":"0","endTime":"0","summary":"华北制药(600812.SH)公告称，公司下属控股子公司金坦公司收到国家药监局核准签发的六价重组诺如病毒疫苗(汉逊酵母)《药物临床试验批准通知书》，同意开展预防六种诺如病毒基因型感染引起的急性胃肠炎临床试验。截至2026年7月，该药品累计研发费用2453.75万元。目前全球尚无获批上市的诺如病毒疫苗，金坦公司已形成“四价+六价”梯次布局。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100040625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","159646","600812","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657523938","title":"华北制药（600812）披露高级管理人员辞职公告，8月5日股价下跌2.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657523938","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657523938?lang=zh_cn&edition=full","pubTime":"2026-08-05 22:31","pubTimestamp":1785940273,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘，华北制药报收于4.76元，较前一交易日下跌2.26%，最新总市值为81.67亿元。近日，华北制药股份有限公司披露《关于高级管理人员辞职的公告》。公告显示，公司董事会于2026年8月4日收到副总经理常志山先生递交的书面辞职报告。常志山先生因工作原因申请辞去公司副总经理职务，辞职后不再担任公司任何职务。其辞职报告自送达董事会之日起生效。公司董事会对常志山先生在职期间为公司发展作出的贡献表示感谢。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500043618.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600812","BK0028","BK0191","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657467495","title":"华北制药：副总经理常志山因工作原因辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2657467495","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657467495?lang=zh_cn&edition=full","pubTime":"2026-08-05 19:00","pubTimestamp":1785927600,"startTime":"0","endTime":"0","summary":"8月5日，华北制药（维权）（600812）发布公告，常志山因工作原因，申请辞去公司副总经理职务，之后不再担任公司任何职务。2026年一季度，华北制药实现收入21.53亿元，归母净利润3547万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/zqgd/2026-08-05/doc-inimhiei4582459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0191","BK0239","600812","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656057273","title":"股市必读：华北制药新发布《关于公司及下属子公司药品参与全国药品集中采购拟中选的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656057273","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656057273?lang=zh_cn&edition=full","pubTime":"2026-08-04 02:04","pubTimestamp":1785780259,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘，华北制药报收于4.86元，上涨0.83%，换手率0.69%，成交量11.76万手，成交额5707.35万元。公司公告汇总：华北制药及下属子公司8个药品拟中选第十二批全国药品集采，采购周期至2029年12月31日。拟中选结果公示期为2026年7月31日至8月5日。相关产品2025年度及2026年第一季度销售收入占公司营业收入比例较小，预计短期内对公司业绩影响有限。后续采购合同签订及销售执行存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400001544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600812","BK0191","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656324077","title":"华北制药(600812.SH)：环孢素软胶囊等药品拟中选全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2656324077","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656324077?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:52","pubTimestamp":1785747130,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华北制药 发布公告，近日，公司及下属子公司华北制药河北华民药业有限责任公司、深圳华药南方制药有限公司参加了国家组织药品联合采购办公室组织的第十二批全国药品集中采购的投标工作。本次公司及华民公司、南方公司参加的第十二批全国药品集中采购8个品种全部拟中选。本次集中采购是国家组织的第十二批药品集中带量采购，采购周期中，医疗机构将优先使用本次药品集中带量采购中选品种，并确保完成约定采购量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475274.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0191","BK0028","BK0239","600812"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655936293","title":"冀中能源集团华北制药两项成果获评全国质量创新专业Ⅱ级奖项","url":"https://stock-news.laohu8.com/highlight/detail?id=2655936293","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655936293?lang=zh_cn&edition=full","pubTime":"2026-07-31 21:32","pubTimestamp":1785504720,"startTime":"0","endTime":"0","summary":"近日，第七届全国质量创新与质量改进成果交流活动成功举办。冀中能源集团华北制药华民公司参与的《注射用头孢噻吩钠分装工艺控制技术研究与应用》和《头孢类原料药中基因毒性杂质M和DM检测方法的开发》两项成果获评全国质量创新专业Ⅱ级奖项。本次活动汇聚航天军工、高端制造、医药、汽车等多行业数百家企业，共计580余项成果同台竞技。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-07-31/doc-iniktkaz4353545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0191","000937","BK0188","BK0028","BK0239","BK0266","600812"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646331348","title":"每周股票复盘：华北制药（600812）获甲苯磺酸艾多沙班片注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2646331348","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646331348?lang=zh_cn&edition=full","pubTime":"2026-06-28 02:31","pubTimestamp":1782585069,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，华北制药报收于4.2元，较上周的4.38元下跌4.11%。本周，华北制药6月24日盘中最高价报4.66元。华北制药当前最新总市值72.06亿元，在化学制药板块市值排名66/150，在两市A股市值排名2414/5206。该药品为口服抗凝药，用于非瓣膜性房颤患者预防卒中及治疗深静脉血栓和肺栓塞等适应症。目前已有包括公司在内多家企业持有该药品注册证书，2024年和2025年销售额分别为4.9亿元和6.1亿元。产品获批后可安排生产和上市销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0191","BK0028","600812"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645990888","title":"华北制药（600812）披露获得甲苯磺酸艾多沙班片《药品注册证书》，6月24日股价上涨0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645990888","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645990888?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:48","pubTimestamp":1782294520,"startTime":"0","endTime":"0","summary":"截至2026年6月24日收盘，华北制药报收于4.49元，较前一交易日上涨0.9%，最新总市值为77.04亿元。华北制药股份有限公司近日收到国家药品监督管理局核准签发的甲苯磺酸艾多沙班片《药品注册证书》，该产品符合药品注册有关要求，批准注册并视为通过仿制药质量和疗效一致性评价。目前已有包括公司在内多家企业持有该药品注册证书，2024年和2025年销售额分别为4.9亿元和6.1亿元。产品获批后可安排生产和上市销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400033207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600812","BK0191","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645843898","title":"华北制药(600812.SH)：甲苯磺酸艾多沙班片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2645843898","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645843898?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:58","pubTimestamp":1782205108,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华北制药(600812.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的甲苯磺酸艾多沙班片(30mg、60mg)《药品注册证书》，甲苯磺酸艾多沙班片是一种口服抗凝药物，用于伴有一个或多个风险因素的非瓣膜性房颤(NVAF)成人患者预防卒中和体循环栓塞;以及用于治疗成人深静脉血栓(DVT)和肺栓塞(PE)，预防成人深静脉血栓和肺栓塞复发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457495.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","600812","BK0191","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644670484","title":"华北制药：公司对高级管理人员实施岗位目标责任制和绩效评价为中心的考核制度","url":"https://stock-news.laohu8.com/highlight/detail?id=2644670484","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644670484?lang=zh_cn&edition=full","pubTime":"2026-06-18 17:43","pubTimestamp":1781775801,"startTime":"0","endTime":"0","summary":"证券之星消息，华北制药06月18日在投资者关系平台上答复投资者关心的问题。持续10年公司以上都没有一点重大利好消息出来华北制药回复：尊敬的投资者，您好。公司对高级管理人员实施岗位目标责任制和绩效评价为中心的考核制度，从经营管理等方面对公司高级管理人员进行考核，将高管人员的薪酬收入与公司发展相挂钩，以适应公司发展的需要。公司高级管理人员的聘任程序公开、透明，符合法律法规及《公司章程》规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800031700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600812","BK0191","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644704850","title":"华北制药：目前没有回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2644704850","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644704850?lang=zh_cn&edition=full","pubTime":"2026-06-18 17:43","pubTimestamp":1781775799,"startTime":"0","endTime":"0","summary":"证券之星消息，华北制药(600812)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问：公司市值股价二级市场表现贵司认为符合正常范围吗？没有考虑回购等措施提振信息吗？华北制药回复：尊敬的投资者，您好。二级市场股价易受多重市场外部因素影响。目前没有回购计划。若有相关计划，公司将按照有关法律法规等规定及时履行信息披露义务。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800031697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","600812","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644010027","title":"华北制药：2026年将继续围绕“五大板块”协同发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2644010027","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644010027?lang=zh_cn&edition=full","pubTime":"2026-06-18 17:42","pubTimestamp":1781775743,"startTime":"0","endTime":"0","summary":"证券之星消息，华北制药06月18日在投资者关系平台上答复投资者关心的问题。二级市场股价易受多重市场外部因素影响。2026年，公司将继续围绕“五大板块”协同发展，持续深化改革，推动营销变革，突出科技引领，夯实管理根基，奋力推动公司高质量发展。公司2026年经营计划，敬请查阅《2025年年度报告》第三节管理层讨论与分析中“经营计划”部分内容。感谢您对公司的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800031654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600812","BK0028","BK0239","BK0191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644670488","title":"华北制药：公司生产经营活动正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2644670488","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644670488?lang=zh_cn&edition=full","pubTime":"2026-06-18 17:42","pubTimestamp":1781775741,"startTime":"0","endTime":"0","summary":"证券之星消息，华北制药(600812)06月18日在投资者关系平台上答复投资者关心的问题。投资者提问：高管需要自查一下自己的工作了华北制药回复：尊敬的投资者，您好。二级市场股价易受多重市场外部因素影响。公司严格按照相关法律法规要求开展各项工作，目前公司生产经营活动正常。感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800031650.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0028","BK0239","600812"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638953442","title":"华北制药（600812）披露获得罗沙司他胶囊《药品注册证书》，5月25日股价下跌1.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638953442","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638953442?lang=zh_cn&edition=full","pubTime":"2026-05-25 18:12","pubTimestamp":1779703942,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘，华北制药报收于4.62元，较前一交易日下跌1.07%，最新总市值为79.27亿元。该股当日开盘4.68元，最高4.71元，最低4.56元，成交额达8073.03万元，换手率为1.02%。华北制药股份有限公司近日收到国家药品监督管理局核准签发的罗沙司他胶囊《药品注册证书》，批准注册并视为通过仿制药质量和疗效一致性评价。该药品适用于慢性肾脏病引起的贫血，包括透析及非透析患者。截至目前，公司累计研发投入1153.27万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500025989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","600812","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637375592","title":"每周股票复盘：华北制药（600812）获罗沙司他胶囊注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2637375592","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637375592?lang=zh_cn&edition=full","pubTime":"2026-05-24 03:31","pubTimestamp":1779564668,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，华北制药报收于4.67元，较上周的5.05元下跌7.52%。本周关注点来自公司公告汇总：华北制药获罗沙司他胶囊《药品注册证书》，视为通过仿制药一致性评价。2025年年度股东会决议公告华北制药股份有限公司于2026年5月20日召开2025年年度股东会，会议采用现场与网络投票结合方式，由王立鑫主持。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400001015.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","600812","BK0191","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637318265","title":"华北制药最新公告：获得罗沙司他胶囊药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2637318265","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637318265?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:51","pubTimestamp":1779443460,"startTime":"0","endTime":"0","summary":"华北制药(600812.SH)公告称，公司收到国家药监局核准签发的罗沙司他胶囊(20mg、50mg)《药品注册证书》。该药品适用于慢性肾脏病引起的贫血，包括透析及非透析患者。截至目前，累计研发投入1153.27万元。该产品获批后，公司可安排生产并上市销售，有效完善了免疫抑制领域的产品结构。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200035664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0191","BK0239","600812"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637826603","title":"华北制药（600812）披露2025年年度股东会决议公告，5月21日股价下跌1.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637826603","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637826603?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:22","pubTimestamp":1779358936,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，华北制药报收于4.77元，较前一交易日下跌1.04%，最新总市值为81.84亿元。该股当日开盘4.82元，最高4.89元，最低4.75元，成交额达7325.71万元，换手率为0.89%。华北制药于2026年5月21日发布《2025年年度股东会决议公告》。公告显示，公司于2026年5月20日召开2025年年度股东会，会议采用现场与网络投票结合方式，由王立鑫主持。出席会议股东共398人，代表有表决权股份969,423,949股，占公司总股本的56.5021%。所有议案均获通过，无否决议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100036328.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0191","BK0028","600812","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787899578247,"stockEarnings":[{"period":"1week","weight":-0.037},{"period":"1month","weight":0.0399},{"period":"3month","weight":0.099},{"period":"6month","weight":-0.1059},{"period":"1year","weight":-0.2228},{"period":"ytd","weight":-0.0977}],"compareEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0.0376},{"period":"3month","weight":-0.0275},{"period":"6month","weight":-0.0496},{"period":"1year","weight":0.0411},{"period":"ytd","weight":-0.0031}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华北制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"88579人(较上一季度减少3.51%)","perCapita":"19369股","listingDate":"1994-01-14","address":"河北省石家庄市长安区和平东路388号","registeredCapital":"171573万元","survey":" 华北制药股份有限公司的主营业务是医药产品的研发、生产和销售。公司的主要产品是化学药、生物药、维生素及健康消费品、农兽药。","listedPrice":4},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华北制药(600812)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华北制药(600812)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华北制药,600812,华北制药股票,华北制药股票老虎,华北制药股票老虎国际,华北制药行情,华北制药股票行情,华北制药股价,华北制药股市,华北制药股票价格,华北制药股票交易,华北制药股票购买,华北制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华北制药(600812)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华北制药(600812)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}